DiaMedica Therapeutics Inc. (DMAC) Revenue History
Annual and quarterly revenue from 2004 to present
DMAC Revenue Over Time (2004–2025)
DMAC Revenue Growth History
2 of 5 years with positive growth- FY2004 revenue growth
- N/A
- FY2005 revenue growth
- -24.2%
- FY2006 revenue growth
- +0.2%
- FY2007 revenue growth
- +524.1%
- FY2008 revenue growth
- -100.0%
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- -100.0%
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
DMAC Revenue Analysis (2004–2025)
Current Revenue & Growth
As of June 22, 2026, DiaMedica Therapeutics Inc. (DMAC) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
DMAC's historical revenue data shows various trends over time. DiaMedica Therapeutics Inc.'s highest annual revenue of $500,000 was recorded in 2018.
Peer Comparison
Compared to Healthcare sector peers — including ACMR (+19.7% YoY), and ANIK (+23.2% YoY). Compare DMAC vs ACMR →
DMAC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DMACCurrent | $0 | - | - | - | |
 ACMR | $901M | +19.7% | +41.9% | 12.1% | |
 ANIK | $113M | +23.2% | -2.9% | -9.8% |
DMAC Historical Revenue Data (2004–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-34,397,000 | - |
| 2024 | $0 | - | $0 | - | $-26,681,000 | - |
| 2023 | $0 | - | $0 | - | $-21,267,000 | - |
| 2022 | $0 | - | $0 | - | $-14,001,000 | - |
| 2021 | $0 | - | $0 | - | $-13,646,000 | - |
| 2020 | $0 | - | $0 | - | $-12,699,000 | - |
| 2019 | $0 | -100.0% | $0 | - | $-11,593,000 | - |
| 2018 | $500K | - | $500K | 100.0% | $-6,761,000 | -1352.2% |
| 2017 | $0 | - | $-4,000 | - | $-4,519,000 | - |
| 2016 | $0 | - | $-2,211 | - | $-2,481,460 | - |
| 2015 | $0 | - | $-4,460 | - | $-1,309,428 | - |
| 2014 | $0 | - | $0 | - | $-4,833,926 | - |
| 2013 | $0 | - | $0 | - | $-7,427,255 | - |
| 2012 | $0 | - | $0 | - | $-10,105,897 | - |
| 2011 | $0 | - | $0 | - | $-6,708,945 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMAC — Frequently Asked Questions
Quick answers to the most common questions about buying DMAC stock.
Is DMAC's revenue growth accelerating or slowing?
DMAC TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DMAC's revenue history from 2004 to 2026?
DiaMedica Therapeutics Inc. (DMAC) revenue history spans 2004 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DMAC's long-term revenue growth rate (CAGR)?
DiaMedica Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DMAC.
Why does DMAC's quarterly revenue fluctuate?
DMAC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. DiaMedica Therapeutics Inc.'s revenue data from 2004 to 2026 shows full historical quarterly detail on this page.
How is DMAC's revenue distributed by segment?
DMAC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DMAC's revenue compare to industry peers?
DiaMedica Therapeutics Inc. (DMAC) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.